What is Generalized pustular psoriasis?
Generalized pustular psoriasis (GPP) is a rare, severe form of psoriasis characterized by widespread sterile pustules across the body, accompanied by fever and systemic inflammation. Unlike the more common plaque psoriasis, GPP represents a medical emergency that can be life-threatening without prompt treatment. This condition affects people of all ages and ethnicities, though it is exceptionally rare, occurring in fewer than 1 in 100,000 individuals worldwide. GPP can develop suddenly in people with no prior history of psoriasis or emerge as a complication in those with existing psoriatic disease.
Key statistics
| Prevalence | Less than 1 in 100,000 people |
| Age of onset | Any age; peaks in 40s-50s |
| Gender distribution | Slightly more common in women |
| Mortality rate | 5-10% without treatment |
Symptoms
Primary symptoms include widespread sterile pustules, high fever, severe skin pain, systemic inflammation, fatigue, and elevated white blood cell count.
The hallmark of GPP is the sudden appearance of small, sterile pustules that spread rapidly across large areas of the body within hours to days. These pustules typically appear on red, inflamed skin and may merge to form “lakes of pus.” Patients experience high fever, often exceeding 39°C (102°F), accompanied by chills and severe malaise. The affected skin becomes extremely tender and painful, making movement difficult.
Systemic symptoms include profound fatigue, muscle weakness, and joint pain. Many patients develop dehydration due to increased fluid loss through the inflamed skin. Laboratory tests reveal leukocytosis (elevated white blood cell count), increased inflammatory markers, and sometimes electrolyte imbalances. Some individuals experience nail changes, including pitting and separation from the nail bed.
The condition can affect mucous membranes, causing painful lesions in the mouth and genital areas. Patients may also develop conjunctivitis and experience difficulty eating or swallowing when oral lesions are present.
Causes and risk factors
GPP has both genetic and environmental components. Approximately 25-30% of cases are associated with mutations in the IL36RN gene, which encodes interleukin-36 receptor antagonist. This protein normally helps regulate inflammatory responses in the skin. When defective, it leads to uncontrolled activation of the interleukin-36 pathway, triggering the characteristic pustular inflammation.
Other genetic factors include mutations in CARD14, AP1S3, and MPO genes, though IL36RN remains the most common genetic cause. Many cases have no identifiable genetic mutation, suggesting additional unknown genetic factors or purely environmental triggers.
Risk factors include existing psoriasis, pregnancy (impetigo herpetiformis), certain medications (lithium, antimalarials, systemic corticosteroid withdrawal), infections, stress, and hypocalcemia. Rapid withdrawal of systemic corticosteroids is a particularly important trigger that healthcare providers must carefully manage in psoriasis patients.
Prevention
Primary prevention of GPP is not currently possible for genetically predisposed individuals. However, genetic testing and counseling can help identify carriers of IL36RN mutations and inform family planning decisions. Carrier frequency varies by population, with some founder mutations identified in specific ethnic groups.
Secondary prevention focuses on avoiding known triggers in susceptible individuals. This includes careful management of existing psoriasis, gradual tapering of corticosteroids rather than abrupt discontinuation, prompt treatment of infections, stress management, and maintaining adequate calcium levels. Patients with known genetic mutations should work closely with dermatologists to develop personalized prevention strategies.
Genetic counseling is recommended for affected individuals and their families, as the condition can follow an autosomal recessive inheritance pattern for IL36RN-associated cases.
Complications
Without prompt treatment, GPP can lead to serious complications including sepsis, cardiovascular collapse, acute kidney injury, and death. The extensive skin inflammation causes significant fluid and protein loss, leading to dehydration, electrolyte imbalances, and malnutrition.
Secondary bacterial infections can occur through damaged skin, potentially progressing to sepsis. The systemic inflammatory response can affect multiple organ systems, causing acute kidney injury, liver dysfunction, and cardiovascular stress. Respiratory complications may develop due to fluid shifts and systemic inflammation.
Long-term complications include permanent skin scarring, nail dystrophy, and increased risk of developing chronic plaque psoriasis. Some patients experience recurrent episodes, which can impact quality of life and require ongoing medical management.
Diagnosis
Diagnosis relies primarily on clinical presentation, supported by laboratory tests and sometimes genetic testing. Key diagnostic criteria include acute onset of sterile pustules, fever, elevated inflammatory markers, and characteristic histological findings on skin biopsy.
Blood tests typically reveal leukocytosis with neutrophilia, elevated C-reactive protein and erythrocyte sedimentation rate, and sometimes electrolyte abnormalities. Bacterial cultures from pustules are negative, confirming their sterile nature.
Skin biopsy shows characteristic histological features including subcorneal pustules filled with neutrophils, acanthosis, and dermal inflammation. Immunohistochemistry may reveal increased interleukin-36 signaling.
Genetic testing for IL36RN and other associated genes can confirm hereditary forms and inform family counseling. This testing is particularly important for patients with early-onset disease, family history, or recurrent episodes.
Differential diagnosis includes acute generalized exanthematous pustulosis (AGEP), bacterial infections, and drug reactions, which must be excluded through appropriate testing.
Treatment
Treatment focuses on rapid control of inflammation and supportive care. Spesolimab, a monoclonal antibody targeting interleukin-36 receptor, was specifically approved for GPP and represents a significant advancement in treatment.
First-line treatments include systemic retinoids such as acitretin and immunosuppressive agents like cyclosporine or methotrexate. Spesolimab has shown particular efficacy in clinical trials and may become preferred first-line therapy.
Biologic therapies including TNF-alpha inhibitors like infliximab and interleukin-17 inhibitors such as secukinumab have shown effectiveness. Anakinra, an interleukin-1 receptor antagonist, has demonstrated efficacy in IL36RN-deficient patients.
Supportive care includes fluid and electrolyte replacement, temperature management, pain control, and prevention of secondary infections. Topical therapies with emollients and mild corticosteroids may provide symptomatic relief but are not sufficient as monotherapy.
Prognosis
With appropriate treatment, the prognosis for GPP has improved significantly. Mortality rates have decreased from historical levels of 20-30% to current rates of 5-10% with modern therapy. Early recognition and prompt treatment are crucial for optimal outcomes.
Most patients respond to treatment within days to weeks, with resolution of pustules and systemic symptoms. However, some individuals may experience recurrent episodes requiring ongoing management. The introduction of targeted therapies like spesolimab has further improved outcomes and quality of life.
Long-term prognosis varies depending on underlying genetic factors, trigger avoidance, and access to appropriate therapy. Patients with IL36RN mutations may have different treatment responses and recurrence patterns compared to those without identified genetic causes.
Quality of life
GPP significantly impacts quality of life during acute episodes and may have lasting effects. The sudden onset and severity can be traumatic, leading to anxiety about future episodes. Pain management and psychological support are essential components of comprehensive care.
During recovery, gentle skincare routines help restore skin barrier function. Patients should use fragrance-free moisturizers and avoid harsh soaps or chemicals. Stress management techniques, including meditation and counseling, may help prevent triggers.
Dietary considerations include maintaining adequate nutrition and hydration, particularly during acute episodes. Some patients benefit from anti-inflammatory diets, though specific dietary interventions lack strong evidence.
Employment considerations may include temporary disability during acute episodes and potential long-term accommodations for those with recurrent disease. Patient advocacy organizations provide valuable resources for navigating these challenges.
Pregnancy and fertility
GPP can occur during pregnancy, traditionally called impetigo herpetiformis, typically in the third trimester. This represents a medical emergency requiring immediate specialist care. The condition may recur in subsequent pregnancies.
Fertility is generally not directly affected by GPP, but some treatments may impact reproductive health. Methotrexate and acitretin are contraindicated during pregnancy and require careful contraception and planning.
Genetic counseling is important for individuals with known mutations, as IL36RN-associated GPP follows autosomal recessive inheritance. Partners can undergo carrier testing to assess recurrence risks.
Children
Pediatric GPP is extremely rare but can be severe when it occurs. Children with IL36RN mutations may present earlier and have more frequent recurrences. Treatment principles are similar to adults but require careful dosing adjustments and consideration of growth and development impacts.
Family genetic testing may be appropriate when a child is diagnosed, as this can identify carrier parents and inform counseling for future pregnancies.
When to see a doctor
Immediate medical attention is required for sudden onset of widespread pustules, especially when accompanied by fever. This represents a dermatological emergency requiring hospitalization and specialist care.
Urgent evaluation is needed for high fever (over 39°C), signs of dehydration, severe skin pain, or systemic symptoms. Patients with known GPP should have emergency action plans and direct access to specialist care.
Routine follow-up with dermatology is important for monitoring and prevention strategies, even during remission periods.
Regional context
Limited data exists on GPP prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean. Some founder mutations have been identified in specific populations, suggesting possible regional clustering. The Global Medical Journal welcomes contributions from regional specialists to better understand local prevalence patterns and genetic variants in these populations.
Research and clinical trials
Current research focuses on understanding interleukin-36 pathway dysfunction and developing targeted therapies. Spesolimab represents the first GPP-specific treatment, with ongoing studies evaluating its long-term efficacy and optimal dosing strategies.
Investigational therapies include other interleukin-36 pathway inhibitors, combination therapies, and personalized approaches based on genetic profiling. Gene therapy approaches are being explored for monogenic forms.
Clinical trials can be found at ClinicalTrials.gov using search terms “generalized pustular psoriasis” or “GPP.” Patients may benefit from discussing trial participation with their specialists.
Frequently asked questions
Is GPP contagious?
No, GPP is not contagious. The pustules are sterile and cannot be transmitted to others through contact.
Will GPP definitely recur after the first episode?
Recurrence varies significantly between individuals. Some experience single episodes while others have recurrent flares. Genetic factors and trigger avoidance influence recurrence risk.
Can I have children if I have GPP?
Pregnancy is possible but requires careful planning and specialist care. Genetic counseling is recommended to understand inheritance risks and plan appropriate monitoring.
Are there dietary restrictions with GPP?
No specific dietary restrictions are required, though maintaining good nutrition supports overall health. Some patients find anti-inflammatory diets helpful, but this lacks strong scientific evidence.
How long does treatment take to work?
Response varies by treatment and individual factors. Spesolimab may show effects within days, while other treatments may take weeks. Early intervention generally leads to faster response.
Support and resources
– National Psoriasis Foundation: www.psoriasis.org
– Orphanet: www.orpha.net
– Global Psoriasis Atlas: www.globalpsoriasisatlas.org
– EURORDIS (European rare disease organization): www.eurordis.org
– National Organization for Rare Disorders (NORD): rarediseases.org
Related conditions
– Plaque psoriasis
– Acute generalized exanthematous pustulosis
– Palmoplantar pustulosis
– Behçet’s disease
– Periodic fever syndromes
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Generalized pustular psoriasis.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/generalized-pustular-psoriasis/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?